| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Cisplation and 5FU are still mainstream chemotherapy drugs for head and neck carcinoma. We focused of protein and mRNA levels to gain higher precision result for identifying the chemoresistant factors.We used human HNSCC cell lines, cisplatin-sensitive, acquired cisplatin resistance, naturally cisplatin-resistant, and acquired 5-fluorouracil resistance. We performed proteomics analysis using iTRAQ and LC-ESI-MS/MS. We also did transcriptomics analysis using microarray. After integrating data, S100A2 a cisplatin-specific factor and BASP1 as multi-chemoresistance factor were identified. Functional analysis revealed expression S100A2 was reduced and recovered the cisplatin sensitivity.
This is a new frontier technique that will provide highly precise identifications as thinking of comprehensive analysis. Our findings indicate that these proteins can be used as criteria biomarkers for chemoresistance for head and neck cancer treatment.
|
